The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for a renewed indication of GlaxoSmithKline’s (GSK) shingles (herpes zoster) vaccine, Shingrix (recombinant zoster vaccine, adjuvanted [RZV)]).

This vaccine is indicated for usage in adults aged 18 years and above who are at higher risk of the condition.

The latest approval, which expands the number of individuals who can receive protection from infection, was based on the findings from six clinical trials in adults.

The non-live, recombinant sub-unit adjuvanted vaccine, RZV, initially obtained approval from the regulatory agency in 2018 for preventing shingles in adults aged 50 years and above.

The vaccine comprises an antigen, glycoprotein E, and AS01B, an adjuvant system. It could aid in combating the age-associated reduction in immunisation response experienced by older people.

RZV is not intended for use in the prevention of primary varicella infection (chickenpox).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This vaccine is currently available in more than 30 countries to prevent shingles in adults aged 50 years and above, and in those 18 and over at higher risk.

The latest development comes after the US Food and Drug Administration (FDA) extended the review period of GSK’s new drug application for momelotinib to treat myelofibrosis by three months.